pivot therapeut announc 2014 financi result pr newswirewoodbridg april 30 onapril 30 pivot therapeut inc otcqx pvttf cse pvo specialti pharmaceut compani focus omega3 therapi cardiovascular diseas cvd overal health announc oper highlight financi result fiscal year end decemb 31 2014 dollar amount referenc herein canadian dollar unless otherwis state pivot accomplish 2014 signific right strateg partner addit capit 2015 investor look forward realist valuat compani state mr eugenio bortoluzzi pivot ceo cfohighlight notic allow uniqu 61 epadha formul conjunct antiobes agent reduct bodi weight cardiovascular diseas patient diabet announc adjust term expans close debt financ result gross proceed cdn two poster discuss omega3 defici vascazen uniqu formul correct defici american heart associ arteriosclerosi thrombosi vascular biolog atvb 2014 scientif session toronto canadaissu us formul compris omega3 fatti acid antiobes agent reduct bodi weight cvd patient diabet enter memorandum understand creat joint ventur acgt corpor effort explor commerci opportun chinapubl byplo onereport studi confirm vascazenformul superior exist commerci product marketplac term sustain coronari vasodil increas blood flow import patient coronari heart diseas compromis coronari vessel present poster indic chronic intak vascazen 61 epadha formul prevent develop hypertens endotheli dysfunct rodent model 2014 annual meet european societi cardiolog congress barcelona spainpubl thevascazenrev trial show posit effect vascazenin correct omega3 defici cardiovascular patient avail peerreview journal titl molecular cellular biochemistrymcb open public access receiv notic allow us patent applic 13584480 titl statin omega3 fatti acid reduct apolipoproteinb level receiv notic allow us patent applic number 13584403 titl cholesterol absorpt inhibitor omega3 fatti acid reduct cholesterol prevent reduct cardiovascular cardiac vascular event announc creation new product line benefishialspecif sold otc direct retail direct consum market benefishialdifferenti otc product greater 90 pure uniqu formul back clinic data announc rd effort resourc use develop reagent rapid format pointofcar poc diagnost test easili identifi patient omega3 defici physician offic clinic pharmaci announc clearanc french fda clinic evalu part pomega phase iiatrial protocolsubsequ year endreceiv final approv conduct pomega phase iiaclin trial proprietari formul stabil vulner plaqu patient undergo carotid endarterectomi surgic procedur remov materi accumul arteri reduc risk stroke issuanc two patent allow q4 2014 us patent number combin ofvascazenwith key cholesterol lower agent statin us patent number combin ofvascazenwith cholesterol absorpt inhibitor receiv notic allow us patent applic number 13584428 relat kit dietari manag cardiovascular patient includ vascazenand omega3 fatti acid diagnost assay execut memorandum understand korea anim medic scienc institut kamsi newli creat affili exclus sale distribut benefishialfamili product koreareceiv health canada approv expand indic omazento includ product claim maintain support cardiovascular health normal triglycerid level 2014 financi reviewfor twelv month endeddecemb 31 compani report loss of54 million common share compar loss 30 million common share twelv month end decemb 31 2013 major item contribut loss increas sell market expens previous year stock base compens nil previous year research develop expens three twelv month end decemb 31 compar three twelv month end decemb 31 2013 annual sale increas slight compar previous year fourth quarter sale achiev increas 42 compar previous year audit consolid financi statement accompani note thereto manag discuss analysi year end decemb 31 2014 access symbol pvo symbol pvttfabout pivot therapeut incpivot therapeut public trade otcqxpvttf csepvo specialti pharmaceut compani focus cardiovascular diseas overal health pivot therapeut lead product vascazeni prescript medic food formul meet dietari omega3 defici need patient cardiovascular diseas elev eicosapentaeno acid epa docosahexaeno acid dha level associ reduc risk cardiovascular complic omazeni pharmaceut grade omega3 provid 90 pure omega3 capsul mainten good health omazeni patent product avail sale distribut canadafor profession marketbenefishi first product pivot new nutraceut product line specif design sold otc direct retail direct consum market vascazenvascazeni current avail us prescript medic food specif formul dietari manag omega3 defici cardiovascular patient vascazeni 90 pure omega3 proprietari 61 epadha fatti acid formul protect seri us foreign patent vascazenha clinic shown correct omega3 defici within eight week treatment posit concomit effect lipid profil main 48 reduct triglycerid increas hdl without negat impact ldlc lipid profil aboutomazenomazeni pivot second commerci product market avail sale distribut profession counter otc market canadaomazencontain greater 90 pure pharmaceut grade omega3 uniqu ratio epa dha mainten good health omazen like pivot product back clinic data scientif support provid superior altern current avail market aboutbenefishialbenefishialwa creat cornerston new nutraceut product line includ prenat children heart anim health orient product benefishiali design sold nutraceut otc direct retail direct consum market us canadabenefishialcontain highest content omega3 fatti acid otc product market specif formul give highest puriti highest antiinflammatori properti best therapeut effect healthi bodi mind contain optim puriti ratio dose omega3 simpl solut number health risk factor disclosur noticeth inform contain document april 30 2015 press releas contain forwardlook statement forwardlook statement subject number risk assumpt uncertainti could caus pivot actual result differ materi project forwardlook statement statement identifi use word anticip estim expect project forecast intend plan believ project potenti similar express discuss futur oper financi perform event particular factor could caus actual result differ materi forward look statement includ follow pivot inabl obtain addit financ accept term growth cost expens inabl compet other provid compar product risk compani product gain widespread market accept risk relat compani abil maintain cse list forwardlook statement speak date made guarante futur perform compani undertak oblig public updat revis forwardlook statement contain document result new inform futur event develop cse review accept respons adequaci accuraci inform sourc pivot therapeut inc 